BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2014 9:55:00 AM | Browse: 1097 | Download: 801
 |
Received |
|
2012-09-10 18:18 |
 |
Peer-Review Started |
|
2012-09-11 10:17 |
 |
To Make the First Decision |
|
2012-09-20 16:06 |
 |
Return for Revision |
|
2013-01-07 08:16 |
 |
Revised |
|
2013-01-10 22:51 |
 |
Second Decision |
|
2013-03-08 16:51 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-03-09 06:07 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-05-17 20:28 |
 |
Publish the Manuscript Online |
|
2013-05-28 09:36 |
Category |
Oncology |
Manuscript Type |
Autobiography |
Article Title |
Neoadjuvant-intensified treatment for rectal cancer: Time to change?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Daniela Musio, Francesca De Felice, Nadia Bulzonetti, Roberta Guarnaccia, Rossella Caiazzo, Caterina Bangrazi, Nicola Raffetto and Vincenzo Tombolini |
Funding Agency and Grant Number |
|
Corresponding Author |
Daniela Musio, MD, Department of Radiotherapy, Policlinico Umberto I University of Rome "Sapienza", Viale Regina Elena 326, 00161 Rome, Italy. daniela.musio@libero.it
|
Key Words |
Rectal cancer; Neoadjuvant treatment; Intensified radiochemotherapy; Oxaliplatin; Fluorouracil |
Core Tip |
Management of rectal cancer requires a multimodality treatment approach. The objective of this study was to determine whether neoadjuvant-intensified radiochemotherapy, using traditional radiation therapy in combination with oxaliplatin and 5-fluorouracil (5-FU), could improve the overall and disease-free survival rates in patients with locally advanced rectal cancer. Conventional chemotherapeutic strategies typically only use 5-FU infusion. The results from this study indicate that the addition of oxaliplatin to the chemotherapeutic regime enhances the 5-year overall survival rate, facilitates a high rate of sphincter preservation, and reduces the local recurrence rate relative to the traditional strategies previously reported in the literature. Furthermore, oxaliplatin addition was well tolerated by patients, demonstrating an acceptable level of toxicity.
|
Publish Date |
2013-05-28 09:36 |
Citation |
Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: Time to change? World J Gastroenterol 2013; 19(20): 3052-3061 |
URL |
http://www.wjgnet.com/1007-9327/full/v19/i20/3052.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v19.i20.3052 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345